These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 8701941)

  • 1. Isolated recombinant domain of von Willebrand factor displaying increased sensitivity to ristocetin.
    Hayashi T; Ware J; Niiya K; Sakuragawa N
    Am J Hematol; 1996 Aug; 52(4):248-53. PubMed ID: 8701941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the phenotypic abnormality of platelet-type von Willebrand disease in a recombinant glycoprotein Ib alpha fragment.
    Murata M; Russell SR; Ruggeri ZM; Ware J
    J Clin Invest; 1993 May; 91(5):2133-7. PubMed ID: 8486780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a point mutation in type IIB von Willebrand disease illustrating the regulation of von Willebrand factor affinity for the platelet membrane glycoprotein Ib-IX receptor.
    Ware J; Dent JA; Azuma H; Sugimoto M; Kyrle PA; Yoshioka A; Ruggeri ZM
    Proc Natl Acad Sci U S A; 1991 Apr; 88(7):2946-50. PubMed ID: 2011604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel von Willebrand factor mutation (I1372S) associated with type 2B-like von Willebrand disease: an elusive phenotype and a difficult diagnosis.
    Casonato A; Sartorello F; Pontara E; Gallinaro L; Bertomoro A; Grazia Cattini M; Daidone V; Szukowska M; Pagnan A
    Thromb Haemost; 2007 Dec; 98(6):1182-7. PubMed ID: 18064311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Type 2M von Willebrand disease: F606I and I662F mutations in the glycoprotein Ib binding domain selectively impair ristocetin- but not botrocetin-mediated binding of von Willebrand factor to platelets.
    Hillery CA; Mancuso DJ; Evan Sadler J; Ponder JW; Jozwiak MA; Christopherson PA; Cox Gill J; Paul Scott J; Montgomery RR
    Blood; 1998 Mar; 91(5):1572-81. PubMed ID: 9473222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct abnormalities in the interaction of purified types IIA and IIB von Willebrand factor with the two platelet binding sites, glycoprotein complexes Ib-IX and IIb-IIIa.
    De Marco L; Mazzucato M; De Roia D; Casonato A; Federici AB; Girolami A; Ruggeri ZM
    J Clin Invest; 1990 Sep; 86(3):785-92. PubMed ID: 2394830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. von Willebrand factor mutation enhancing interaction with platelets in patients with normal multimeric structure.
    Holmberg L; Dent JA; Schneppenheim R; Budde U; Ware J; Ruggeri ZM
    J Clin Invest; 1993 May; 91(5):2169-77. PubMed ID: 8486782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultralarge multimers of von Willebrand factor form spontaneous high-strength bonds with the platelet glycoprotein Ib-IX complex: studies using optical tweezers.
    Arya M; Anvari B; Romo GM; Cruz MA; Dong JF; McIntire LV; Moake JL; López JA
    Blood; 2002 Jun; 99(11):3971-7. PubMed ID: 12010796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet activation and aggregation induced by recombinant von Willebrand factors reproducing four type 2B von Willebrand disease missense mutations.
    de Romeuf C; Hilbert L; Mazurier C
    Thromb Haemost; 1998 Jan; 79(1):211-6. PubMed ID: 9459349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Membrane fluidity and platelet aggregation: dibucaine permits ristocetin-induced platelet aggregation with low-molecular-weight von Willebrand multimers.
    Gjønnaess E; Solum NO; Brosstad F
    Blood Coagul Fibrinolysis; 1992 Aug; 3(4):395-405. PubMed ID: 1420815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. von Willebrand disease type B: a missense mutation selectively abolishes ristocetin-induced von Willebrand factor binding to platelet glycoprotein Ib.
    Rabinowitz I; Tuley EA; Mancuso DJ; Randi AM; Firkin BG; Howard MA; Sadler JE
    Proc Natl Acad Sci U S A; 1992 Oct; 89(20):9846-9. PubMed ID: 1409710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel 14-3-3zeta binding site within the cytoplasmic domain of platelet glycoprotein Ibalpha that plays a key role in regulating the von Willebrand factor binding function of glycoprotein Ib-IX.
    Yuan Y; Zhang W; Yan R; Liao Y; Zhao L; Ruan C; Du X; Dai K
    Circ Res; 2009 Dec; 105(12):1177-85. PubMed ID: 19875727
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis of subtype 2B von Willebrand disease in a patient with 2A phenotype of plasma von Willebrand factor.
    Gaucher C; de Romeuf C; Rauïs-Morret M; Corazza F; Fondu P; Mazurier C
    Thromb Haemost; 1995 Apr; 73(4):610-6. PubMed ID: 7495067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The cytoplasmic domain of the alpha-subunit of glycoprotein (GP) Ib mediates attachment of the entire GP Ib-IX complex to the cytoskeleton and regulates von Willebrand factor-induced changes in cell morphology.
    Cunningham JG; Meyer SC; Fox JE
    J Biol Chem; 1996 May; 271(19):11581-7. PubMed ID: 8626721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Type 2B Hiroshima: a variant of von Willebrand disease characterized by chronic thrombocytopenia and the presence of all von Willebrand factor multimers in plasma.
    Takimoto Y; Imanaka F
    Int J Hematol; 1999 Aug; 70(2):127-31. PubMed ID: 10497852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A role for von Willebrand factor proline residues 702-704 in ristocetin-mediated binding to platelet glycoprotein Ib.
    Azuma H; Sugimoto M; Ruggeri ZM; Ware J
    Thromb Haemost; 1993 Feb; 69(2):192-6. PubMed ID: 8456433
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of type IIB von Willebrand disease mutation Arg(545)Cys on platelet glycoprotein Ib binding--studies with recombinant von Willebrand factor.
    Inbal A; Kornbrot N; Harrison P; Randi AM; Sadler JE
    Thromb Haemost; 1993 Dec; 70(6):1058-62. PubMed ID: 8165601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dynamic force spectroscopy of glycoprotein Ib-IX and von Willebrand factor.
    Arya M; Kolomeisky AB; Romo GM; Cruz MA; López JA; Anvari B
    Biophys J; 2005 Jun; 88(6):4391-401. PubMed ID: 15764659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of von Willebrand factor binding to a recombinant fragment of glycoprotein Ibalpha in an enzyme-linked immunosorbent assay-based method: performances in patients with type 2B von Willebrand disease.
    Caron C; Hilbert L; Vanhoorelbeke K; Deckmyn H; Goudemand J; Mazurier C
    Br J Haematol; 2006 Jun; 133(6):655-63. PubMed ID: 16704443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new L1446P mutation is responsible for impaired von Willebrand factor synthesis, structure, and function.
    Casonato A; Cattini MG; Soldera C; Marcato S; Sartorello F; Pontara E; Pagnan A
    J Lab Clin Med; 2004 Nov; 144(5):254-9. PubMed ID: 15570243
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.